Rheumatoid arthritis and anti-TNF-α therapy [1]

Atherosclerosis

Volumn 181, Issue 1, 2005, Pages 209-

  Gonzalez Juanatey, Carlos ^a   Gonzalez Gay, Miguel A ^a  

^a HOSPITAL XERAL CALDE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; METHOTREXATE; RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM LESION; HUMAN; INFLAMMATION; LETTER; LONG TERM CARE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SHEAR STRESS; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 20444376926     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.02.031     Document Type: Letter

References (5)

1. C. Irace, G. Mancuso, and E. Fiaschi Effect of anti-TNF-alpha therapy on arterial diameter and wall shear stress and HDL cholesterol Atherosclerosis 177 2004 113 118
2. C. Gonzalez-Juanatey, A. Testa, and A. Garcia-Castelo HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis Am J Med 114 2003 647 652
3. N. Sattar, D.W. McCarey, H. Capell, and I.B. McInnes Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis Circulation 108 2003 2957 2963
4. C. Gonzalez-Juanatey, J. Llorca, and A. Testa Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease Medicine (Baltimore) 82 2003 407 413
5. C. Gonzalez-Juanatey, A. Testa, and A. Garcia-Castelo Active but transient improvement of endothelial function in long-term anti-tumor necrosis-α antibody-infliximab treated rheumatoid arthritis patients Arthritis Rheum 51 2004 447 450